Loading...
Please wait, while we are loading the content...
Similar Documents
Acute myeloid leukemia patients with an activating mutation in flt3 respond to a small molecule flt3 tyrosine kinase inhibitor, pkc412.
| Content Provider | CiteSeerX |
|---|---|
| Author | Neuberg, Donna James, D. Deangelo, Daniel J. Klimek, Virginia Estey, Eli Clark, Jennifer Galinsky, Ilene Lebwohl, David Nimer, Stephen D. Fox, Edward A. Cohen, Pamela Gr, Wilson Wang, Yanfeng Stone, Richard M. Gillil, D. Gary |
| Abstract | *Several of the authors (P.C., D.L, and Y.W.) are employed by a company (Novartis) whose potential product was studied in the present work. This study was supported by research funding from Novartis. Blood First Edition Paper, prepublished online September 2, 2004; DOI 10.1182/blood-2004-03-0891 Copyright © 2004 American Society of Hematology |
| File Format | |
| Access Restriction | Open |
| Content Type | Text |